Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.98 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | NPY2R | P49146 | 12/20 | 0.67 |
| ▸ | MC4R | P32245 | 1/20 | 0.65 |
| ▸ | MC1R | Q01726 | 1/20 | 0.65 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.63 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.62 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.62 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.62 |
| ▸ | RXFP4 | Q8TDU9 | 3/20 | 0.61 |
| ▸ | RXFP3 | Q9NSD7 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15669703 | 0.98 | INSR (0.95) | INSRRXFP1NPY2RMC4RMC1R | |
| SCHEMBL14840198 | 0.97 | INSR (0.93) | INSRRXFP1NPY2RMC4RMC1R | |
| Insulin Detemir SCHEMBL29350489 | 0.91 | INSR (0.82) | INSRRXFP1NPY2RMC4RMC1R | |
| SCHEMBL33618 | 0.87 | INSR (0.75) | INSRRXFP1NPY2RMC4RMC1R | |
| SCHEMBL29385832 | 0.82 | MC4R (0.72) | INSRRXFP1NPY2RMC4RMC1R | |
| Davalintide SCHEMBL29533482 | 0.81 | RAMP1 (0.77) | INSRNPY2R | |
| Calcitonin Salmon SCHEMBL269785 | 0.80 | INSR (0.64) | INSRNPY2R | |
| Amylin SCHEMBL29351499 | 0.80 | RAMP1 (0.75) | INSRRXFP1NPY2RKCNMA1KCNMB4 | |
| Calcitonin Salmon SCHEMBL29392873 | 0.80 | INSR (0.64) | INSRNPY2R | |
| SCHEMBL29367000 | 0.79 | NPY2R (0.68) | INSRNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238382-A1 | URI Agonist/Vasodilator | LILLY CO ELI (US) | 2024-07-18 | — | — | US | disclosed |
| CN-115894720-B | Long-acting insulin-Fc fusion protein | 中国科学院上海药物研究所 | 2024-07-09 | — | — | CN | disclosed |
| US-20240207365-A1 | METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS | XERIS PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024110516-A1 | TOLEROGENIC COMPOSITION | AHEAD THERAPEUTICS, S.L. (ES) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024045890-A1 | PREPARATION METHOD FOR DENDRITIC CELL PROGENITORS AND CULTURE MEDIUM THEREOF | 浙江吉量科技有限公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-117625531-A | Preparation method of dendritic cell progenitor cells and culture medium thereof | 浙江吉量科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4327804-A2 | METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS | Xeris Pharmaceuticals, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024035929-A2 | INSULIN SENSITIZERS FOR REVERSAL OF INSULIN RESISTANCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240041984-A1 | METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS | XERIS PHARMACEUTICALS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11872266-B2 | Rapid-acting insulin compositions | ELI LILLY AND COMPANY (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2014138682-A1 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR | UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014068007-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2014-05-08 | — | — | WO | disclosed |
| US-8129562-B2 | Carboxylic acid derivatives | DSM IP ASSETS B.V. (NL) | 2012-03-06 | — | — | US | disclosed |
| US-20110136241-A1 | TYPE II DIABETES MOLECULAR BIOPROFILE AND METHOD AND SYSTEM OF USING THE SAME | NAYLOR STEPHEN | 2011-06-09 | — | — | US | disclosed |
| US-20110124726-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP ASSETS B.V. | 2011-05-26 | — | — | US | disclosed |
| US-7906496-B2 | Carboxylic acid derivatives | DSM IP ASSETS B.V. (NL) | 2011-03-15 | — | — | US | disclosed |
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | DSM ASSETS B.V. (NL) | 2009-10-15 | — | — | US | disclosed |
| CN-101268039-A | Novel carboxylic acid derivatives | DSM IP ASSETS BV (NL) | 2008-09-17 | — | — | CN | disclosed |
| EP-1926703-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP Assets B.V. (NL) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007039059-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238382-A1 | URI Agonist/Vasodilator | GPR119, INSR, IAPP | INSR 2/4885RXFP1 35/4885NPY2R 147/4885 |
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | AADAC, ALDH7A1, DDC | INSR 2289/4885RXFP1 4773/4885NPY2R 4444/4885 |
| US-20110124726-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | AADAC, ALDH7A1, ALDH18A1 | INSR 2160/4885RXFP1 4719/4885NPY2R 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.